Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK46 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection inhibitor), olomorasib (an investigational KRAS G12C…
Read More...
Read More...